{
  "id": "61f7d5a0882a024a10000035",
  "type": "factoid",
  "question": "Which molecule is targeted by Fenebrutinib?",
  "ideal_answer": "Fenebrutinib is a noncovalent, oral, and highly selective inhibitor of Bruton's tyrosine kinase (BTK).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34750553",
    "http://www.ncbi.nlm.nih.gov/pubmed/31494233",
    "http://www.ncbi.nlm.nih.gov/pubmed/32832028",
    "http://www.ncbi.nlm.nih.gov/pubmed/32270926",
    "http://www.ncbi.nlm.nih.gov/pubmed/33806595",
    "http://www.ncbi.nlm.nih.gov/pubmed/31907670",
    "http://www.ncbi.nlm.nih.gov/pubmed/31446134",
    "http://www.ncbi.nlm.nih.gov/pubmed/33689480",
    "http://www.ncbi.nlm.nih.gov/pubmed/33777941",
    "http://www.ncbi.nlm.nih.gov/pubmed/31371481",
    "http://www.ncbi.nlm.nih.gov/pubmed/34042314"
  ],
  "snippets": [
    {
      "text": "These inhibitors include four Syk inhibitors, Bay 61-3606, R406 (fostamatinib), entospletinib, TAK-659; four irreversible BTK inhibitors, ibrutinib, acalabrutinib, ONO-4059 (tirabrutinib), AVL-292 (spebrutinib); and four reversible BTK inhibitors, CG-806, BMS-935177, BMS-986195, and fenebrutinib. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33689480",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, an increasing number of trials instead addresses autoimmunity and inflammation in multiple sclerosis, rheumatoid arthritis, pemphigus and systemic lupus erythematosus with the use of either irreversibly binding inhibitors, e.g., evobrutinib and tolebrutinib, or reversibly binding inhibitors, like fenebrutinib. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33777941",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: Fenebrutinib (GDC-0853) is a noncovalent, oral, and highly selective inhibitor of Bruton's tyrosine kinase (BTK).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34042314",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In contrast, no bleeding has been reported in clinical trials of other BTKi. These include the brain-penetrant irreversible tolebrutinib and evobrutinib (against multiple sclerosis), the irreversible branebrutinib, the reversible BMS-986142 and fenebrutinib (targeting rheumatoid arthritis and lupus erythematodes), and the reversible covalent rilzabrutinib (against pemphigus and immune thrombocytopenia).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33806595",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bruton's tyrosine kinase (BTK) is crucial for Fc\u03b5RI-mediated mast cell activation and essential for autoantibody production by B cells in chronic spontaneous urticaria (CSU). Fenebrutinib, an orally administered, potent, highly selective, reversible BTK inhibitor, may be effective in CSU. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34750553",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "New therapeutics under investigation include IgG1 anti-IgE monoclonal antibodies (ligelizumab), chemoattractant rector-homologous molecule expressed on TH2 cells antagonists (AZD1981), Bruton tyrosine kinase inhibitors (fenebrutinib), anti-siglec-8 monoclonal antibody (AK002), and topical spleen tyrosine kinase inhibitors (GSK2646264). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31494233",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Fenebrutinib (GDC-0853) is an orally administered small molecule inhibitor of Bruton's tyrosine kinase being investigated for treatment of rheumatoid arthritis in patients with inadequate responses to methotrexate (MTX).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31371481",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Absence of Pharmacokinetic Interactions between the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31371481",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In efforts to develop additional series of reversible Btk inhibitors for chronic immune diseases, we sought to differentiate from our clinical stage inhibitor fenebrutinib using cyclopropyl amide isosteres of the 2-aminopyridyl group to occupy the flat, lipophilic H2 pocket.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32832028",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "erapeutics under investigation include IgG1 anti-IgE monoclonal antibodies (ligelizumab), chemoattractant rector-homologous molecule expressed on TH2 cells antagonists (AZD1981), Bruton tyrosine kinase inhibitors (fenebrutinib), anti-siglec-8 monoclonal antibody (AK002), and topical spleen tyrosine kinase inhibitors (GSK2646264). We review the mechanisms of",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31494233",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "promising drugs that are currently under development for CU are a chemoattractant receptor-homologous molecule expressed on TH2 cell antagonist, a monoclonal antibody to Siglec-8 (AK002), Bruton tyrosine kinase inhibitors (fenebrutinib and Lou064), a spleen tyrosine kinase inhibitor, and dupilumab. Promising targets of future",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31446134",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These inhibitors include four Syk inhibitors, Bay 61-3606, R406 (fostamatinib), entospletinib, TAK-659; four irreversible BTK inhibitors, ibrutinib, acalabrutinib, ONO-4059 (tirabrutinib), AVL-292 (spebrutinib); and four reversible BTK inhibitors, CG-806, BMS-935177, BMS-986195, and fenebrutinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33689480",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: Fenebrutinib (GDC-0853) is a noncovalent, oral, and highly selective inhibitor of Bruton's tyrosine kinase",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34042314",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To evaluate fenebrutinib, an oral and highly selective non-covalent inhibitor of Bruton's tyrosine kinase (BTK), in patients with active rheumatoid arthrit",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32270926",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Fenebrutinib (GDC-0853), a Bruton's tyrosine kinase (BTK) inhibitor was investigated in a Phase 2 clinical trial in patients with rheumatoid arthritis ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31907670",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Fenebrutinib (GDC-0853) is an orally administered small molecule inhibitor of Bruton's tyrosine kinase being investigated for treatment of rheumatoid arthritis in patients with inadequate responses to methotrexate (MTX). T",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31371481",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: Fenebrutinib (GDC-0853) is a noncovalent, oral, and highly selective inhibitor of Bruton's tyrosine ki",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34042314",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Fenebrutinib (GDC-0853), a Bruton's tyrosine kinase (BTK) inhibitor was investigated in a Phase 2 clinical trial in patients with rheumatoid arthri",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31907670",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To evaluate fenebrutinib, an oral and highly selective non-covalent inhibitor of Bruton's tyrosine kinase (BTK), in patients with active rheumatoid arth",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32270926",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "utinib 200 mg twice daily. By week 48, patients treated with fenebrutinib had reduced levels of a BTK-dependent plasmablast RNA signature, anti-double-stranded DNA autoantibodies, total IgG, and IgM, as well as increased complement C4 level",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34042314",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To evaluate fenebrutinib, an oral and highly selective non-covalent inhibitor of Bruton's tyrosine kinase (BTK), in patients with active rheumatoid arthritis (RA).METHODS: Patients with RA and inadequate response to methotrexate (cohort 1, n=480) were randomized to fenebrutinib (50 mg once daily, 150 mg once daily, 200 mg twice daily), 40 mg adalimumab every oth",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32270926",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Fenebrutinib, an orally administered, potent, highly selective, reversible BTK inhibitor, may be effective in CSU.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34750553",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34042314",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "essants; however, additional treatments are needed. New therapeutics under investigation include IgG1 anti-IgE monoclonal antibodies (ligelizumab), chemoattractant rector-homologous molecule expressed on TH2 cells antagonists (AZD1981), Bruton tyrosine kinase inhibitors (fenebrutinib), anti-siglec-8 monoclonal antibody (AK002), and top",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31494233",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "brutinib 200 mg twice daily. By week 48, patients treated with fenebrutinib had reduced levels of a BTK-dependent plasmablast RNA signature, anti-double-stranded DNA autoantibodies, total IgG, and IgM, as well as increased complement C4 levels, all relative to placebo.CONCLUSION: While fenebrutinib had an acceptable safety profile, the primary end point, SRI-4 response, was not met despi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34042314",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Bruton's tyrosine kinase"
}